- Nachrichtendetail
-
21.06.2024 14:05:06 - dpa-AFX: *TAKEDA CANADA GETS APPROVAL FOR HYQVIA AS PRIMARY & SECONDARY IMMUNODEFICIENCY REPLACEMENT THERAPY IN PEDIATRIC PATIENTS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
TAKEDA PHARM.CO.LTD. | 853849 | Frankfurt | 24,700 | 17.07.24 21:50:00 | +0,300 | +1,23% | 24,890 | 25,170 | 24,720 | 24,700 |
